The Endocrine Society studies I have seen at the Society meetings on cancer rates in T2/ DM pts and Metformin RX found 1.5 gms in their population to be cancer protective.
Look at the papers cited on this issue by LEF and also Bill Fallon ‘s editorials.
AGE to start: No age specified . I recommend start when there is any any sign of abnormal glucose metabolism:
Via insulin resistance tests, HBA1C, fasting insulin, glucose, OGTT w/ insulin levels etc.
In general if your HBA1C is climbing over time no matter at what age I would recc Metformin.
If all above is normal I would recc from clinical experience 500 mg twice daily especially those on high leucine and diary product diets ( read meat with low non starch vegetable intake). Leucine and milk proteins, whey seem to drive mTOR pathways.
COST : 10-20 cents per tab (500 mg) at CostCo.
You are allowed to get HBA1C testing every 90 days if there is reason to do so for insurance coverage.
Otherwise order tests online via www.lef.org — blood tests
Regards — Karlis
Best of health
Karlis C. Ullis, MD
Endocrinology, Sports & Preventive Medicine900 Wilshire Blvd.,Suite 425; Santa Monica, CA 90401310.452.1990 Fax: 310.452.5134Email: firstname.lastname@example.org
On Tue, Sep 9, 2014 at 10:32 PM, Thomas Coote wrote:
Thank you for your comments on that paper.
I am a non-diabetic (57 y-o) who has been taking Metformin for about 2 years now, but I am only taking 250mg/day! The doses you quoted seem huge by comparison. Am I wasting my time/money?
Do you have any suggested age at which you recommend starting Metformin?
I presume Metformin would work in synergy with other AMPK activators?
On Wednesday, September 10, 2014, Karlis C. Ullis, M.D. wrote:
This explains why Metformin reduces cancer rates/risk since it activates the AMPK system.
The data for Metformin RX cancer reduction ( prostate, breast, colon, pancreas and others) and cancer RX with Metformin is strong.
The effective Metformin dose is about 1.5 GM is some studies. Some use the Metformin ER once daily.
I recommend 2.0 gm given as 1 gm twice daily to lower risk of acidosis.
Bill Faloon of LEF has been a proponent of 850 mg Metformin 3x/day for long time. Even if you do not have diabetes Metformin is worth taking especially as you get older Glucose metabolism deteriorates subtly and cancer rates go up. That is also why hGH is bad idea since it impairs Glucose metabolism.
Some say the AMPK mechanism may knock-out pre-cancerous Stem Cells.
Best of health
Karlis C. Ullis, MD
Endocrinology, Sports & Preventive Medicine900 Wilshire Blvd.,Suite 425; Santa Monica, CA 90401310.452.1990 Fax: 310.452.5134Email: email@example.com http://ift.tt/1xGFCHF note e-mails may not be checked regularly and should not be used for urgent medical matters. Information contained in this e-mail & attached document(s) may contain confidential information that is intended only for the addressee(s). If you are not intended recipient, you are advised disclosure, copying, distribution, taking any action in response to the information is prohibited. If you have received this e-mail in error, immediately notify sender & delete it.
On Tue, Sep 9, 2014 at 3:00 PM, Patricia Tawfik wrote:
Sent from Yahoo Mail for iPhone
[GRG] Increasing AMPK slows aging
Tue, Sep 9, 2014 8:15:59 PM
http://ift.tt/1tuK45H delay the aging process by ‘remote control’Date:September 8, 2014Source:University of California – Los AngelesSummary:Biologists have identified a gene that can slow the aging process when activated remotely in key organ systems. The life scientists, working with fruit flies, activated a gene called AMPK that is a key energy sensor in cells. Increasing AMPK in the intestine increased the fly’s life by about 30 percent, and the fly stayed healthier longer as well. The research could have important implications for delaying aging and disease in humans.Share ThisActivating a gene called AMPK in the nervous system
induces the anti-aging cellular recycling process of autophagy in both the brain and intestine. Activating AMPK in the intestine leads to increased autophagy in both the intestine and brain. Matthew Ulgherait, David Walker and UCLA colleagues showed that this ‘inter-organ’ communication during aging can substantially prolong the healthy lifespan of fruit flies.Credit: Matthew Ulgherait/UCLA[Click to enlarge image] UCLA biologists have identified a gene that can slow the aging process throughout the entire body when activated remotely in key organ systems. Working with fruit flies, the life scientists activated a gene called AMPK that is a key energy sensor in cells; it gets activated when cellular energy levels are low.Increasing the amount of AMPK in fruit flies’ intestines increased their lifespans by about 30
percent — to roughly eight weeks from the typical six — and the flies stayed healthier longer as well.The research, published Sept. 4 in the open-source journal Cell Reports, could have important implications for delaying aging and disease in humans, said David Walker, an associate professor of integrative biology and physiology at UCLA and senior author of the research.”We have shown that when we activate the gene in the intestine or the nervous system, we see the aging process is slowed beyond the organ system in which the gene is activated,” Walker said.Walker said that the findings are important because extending the healthy life of humans would presumably require protecting many of the body’s organ systems from the ravages of aging — but delivering anti-aging treatments to the brain or other key organs could prove technically difficult. The study suggests that activating
AMPK in a more accessible organ such as the intestine, for example, could ultimately slow the aging process throughout the entire body, including the brain.Humans have AMPK, but it is usually not activated at a high level, Walker said.”Instead of studying the diseases of aging — Parkinson’s disease, Alzheimer’s disease, cancer, stroke, cardiovascular disease, diabetes — one by one, we believe it may be possible to intervene in the aging process and delay the onset of many of these diseases,” said Walker, a member of UCLA’s Molecular Biology Institute. “We are not there yet, and it could, of course, take many years, but that is our goal and we think it is realistic.”The ultimate aim of our research is to promote healthy aging in people.”The fruit fly, Drosophila melanogaster, is a good model for studying aging in humans because scientists have identified all of the fruit
fly’s genes and know how to switch individual genes on and off. The biologists studied approximately 100,000 of them over the course of the study.Lead author Matthew Ulgherait, who conducted the research in Walker’s laboratory as a doctoral student, focused on a cellular process called autophagy, which enables cells to degrade and discard old, damaged cellular components. By getting rid of that “cellular garbage” before it damages cells, autophagy protects against aging, and AMPK has been shown previously to activate this process.Ulgherait studied whether activating AMPK in the flies led to autophagy occurring at a greater rate than usual.”A really interesting finding was when Matt activated AMPK in the nervous system, he saw evidence of increased levels of autophagy in not only the brain, but also in the intestine,” said Walker, a faculty member in the UCLA College. “And vice
versa: Activating AMPK in the intestine produced increased levels of autophagy in the brain — and perhaps elsewhere, too.”Many neurodegenerative diseases, including both Alzheimer’s and Parkinson’s, are associated with the accumulation of protein aggregates, a type of cellular garbage, in the brain, Walker noted.”Matt moved beyond correlation and established causality,” he said. “He showed that the activation of autophagy was both necessary to see the anti-aging effects and sufficient; that he could bypass AMPK and directly target autophagy.”Walker said that AMPK is thought to be a key target of metformin, a drug used to treat Type 2 diabetes, and that metformin activates AMPK.The research was funded by the National Institutes of Health’s National Institute on Aging (grants R01 AG037514 and R01 AG040288). Ulgherait received funding support from a Ruth L. Kirschstein
National Research Service Award (GM07185) and Eureka and Hyde fellowships from the UCLA department of integrative biology and physiology.Co-authors of the research were Anil Rana, a postdoctoral scholar in Walker’s lab; Michael Rera, a former UCLA postdoctoral scholar in Walker’s lab; and Jacqueline Graniel, who participated in the research as a UCLA undergraduate.Story Source:The above story is based on materials provided by University of California – Los Angeles. The original article was written by Stuart Wolpert. Note: Materials may be edited for content and length.Journal Reference:1.Matthew Ulgherait, Anil Rana, Michael Rera, Jacqueline Graniel, David W. Walker. AMPK Modulates Tissue and Organismal Aging in a Non-Cell-Autonomous Manner. Cell Reports, 2014; DOI: 10.1016/j.celrep.2014.08.006 Cite This Page:MLA APA
ChicagoUniversity of California – Los Angeles. “Biologists delay the aging process by ‘remote control’.” ScienceDaily. ScienceDaily, 8 September 2014. .Sent using Hushmail